Concerns about the actual and perceived costs of pre-exposure prophylaxis (PrEP) continue to be a major barrier to uptake among gay, bisexual and men who have sex with men (GBMSM) in the United States.
Methods
We conducted semi-structured interviews with 25 GBMSM who presented for routine health care at a STD clinic in the northeastern United States. The cohort included GBMSM who were or were not currently taking PrEP and represented varied health care coverage and financial resources. We used a structured coding scheme to analyze transcripts and identify themes relevant to cost factors.
Results
Participants shared their perspectives about PrEP and their experiences with accessing and paying for PrEP. Our findings suggest that health care coverage or financial assistance were essential to PrEP access but were not easily accessible to all people and did not always cover all costs. Therefore, paying for PrEP had to be balanced with other life expenses. Participants had multiple sources for information about PrEP cost and assistance from clinic and pharmacy staff helped reduce burden and resolve difficulties.
Conclusion
Addressing gaps in health care coverage, providing financial support, and improving the enrollment process in a financial assistance program may improve PrEP uptake.
CalabreseSKWillieTCGalvaoRW, et al.Current US guidelines for prescribing hiv pre-exposure prophylaxis (PrEP) disqualify many women who are at risk and motivated to use PrEP. JAIDS J Acquired Immune Deficiency Syndromes2019; 81: 395–405.
3.
SullivanPSWoodyattCKoskiC, et al.A data visualization and dissemination resource to support HIV Prevention and care at the local level: analysis and uses of the AIDSVu public data resource. J Med Internet Res2020; 22: e23173.
CrosbyRAGeterADiClementeRJ, et al.Acceptability of condoms, circumcision and PrEP among young black men who have sex with men: a descriptive study based on effectiveness and cost. Vaccines (Basel)2014; 2: 129–137.
6.
D’AngeloABLopez-RiosJFlynnAWP, et al.Insurance- and medical provider-related barriers and facilitators to staying on PrEP: results from a qualitative study. Transl Behav Med2021; 11: 573–581.
7.
HosekSCelumCWilsonCM, et al.Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa. J Int AIDS Soc; 19. DOI: 10.7448/IAS.19.7.21107
8.
MimiagaMJCasePJohnsonCV, et al.Preexposure antiretroviral prophylaxis attitudes in high-risk boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. JAIDS J Acquired Immune Deficiency Syndromes2009; 50: 77–83.
9.
PengPSuSFairleyCK, et al.A Global estimate of the acceptability of pre-exposure prophylaxis for HIV among men who have sex with men: a systematic review and meta-analysis. AIDS Behav2018; 22: 1063–1074.
10.
SaberiPGamarelKENeilandsTB, et al.Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study. PLoS ONE2012; 7: e50061.
11.
SmithDKToledoLSmithDJ, et al.Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev2012; 24: 408–421.
12.
KubicekKArauz-CuadraCKipkeMD. Attitudes and perceptions of biomedical HIV prevention methods: voices from young men who have sex with men. Arch Sex Behav2015; 44: 487–497.
13.
BrooksRAKaplanRLLieberE, et al.Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care2011; 23: 1136–1145.
14.
FurukawaNWSchneiderJAColemanME, et al.Out-of-pocket costs and HIV pre-exposure prophylaxis persistence in a US multicity demonstration project. Health Serv Res2020; 55: 524–530.
15.
WalenskyRPHornTMcCannNC, et al.Comparative pricing of branded tenofovir alafenamide–emtricitabine relative to generic tenofovir disoproxil fumarate–emtricitabine for HIV preexposure prophylaxis. Ann Intern Med2020; 172: 583–590.
16.
CohenRZammittiH. High-deductible health plan enrollment among adults aged 18–64 with employment-based insurance coverage. NCHS Data Brief, no 317. Hyattsville, MD: National Center for Health Statistics, 2018.
17.
KayESPintoRM. Is Insurance a barrier to HIV preexposure prophylaxis? Clarifying the issue. Am J Public Health2020; 110: 61–64.
18.
SmithDKPalsSLHerbstJH, et al.Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr2012; 60: 421–427.
19.
Dedoose Version 8.0.35, web application for managing, analyzing, and presenting qualitative and mixed method research data, SocioCultural Research Consultants, LLC, 2018.
20.
Doblecki-LewisSLiuAFeasterD, et al.Healthcare access and PrEP continuation in San Francisco and Miami After the US PrEP demo project. J Acquir Immune Defic Syndr2017; 74: 531–538.
21.
GrantRMAndersonPLMcMahanV, et al.Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. The Lancet Infect Dis2014; 14: 820–829.
22.
SerotaDPRosenbergESThorneAL, et al.Lack of health insurance is associated with delays in PrEP initiation among young black men who have sex with men in Atlanta, US: a longitudinal cohort study. J Int AIDS Soc2019; 22: e25399.
23.
WatsonCW-MPasipanodyaESavinMJ, et al.Barriers and facilitators to PrEP initiation and adherence among transgender and gender non-binary individuals in southern California. AIDS Educ Prev2020; 32: 472–485.
24.
Pérez-FigueroaREKapadiaFBartonSC, et al.Acceptability of PrEP uptake among racially/ethnically diverse young men who have sex with men: the p18 study. AIDS Educ Prev2015; 27: 112–125.
25.
KoechlinFMFonnerVADalglishSL, et al.Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav2017; 21: 1325–1335.
26.
GolubSAGamarelKERendinaHJ, et al.From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care and STDs2013; 27: 248–254.
27.
GalindoGRWalkerJJHazeltonP, et al.Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. Implement Sci2012; 7: 116.
28.
McKenneyJChenAHooverKW, et al.Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men. PLoS ONE2017; 12: e0178170.
29.
ArdKLWalenskyRP. Payments for preexposure prophylaxis in the United States: too much for too few. Ann Intern Med2020; 173: 844–845.
30.
TurnerLRoepkeAWardellE, et al.Do you PrEP? A review of primary care provider knowledge of PrEP and attitudes on prescribing PrEP. J Assoc Nurses AIDS Care2018; 29: 83–92.
